Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta

Area of Science:

• Bone biology
• Genetics
• Pharmacology

Background:

• Low-density lipoprotein receptor-related protein 5 (LRP5) regulates bone mass and strength.
• Mutations in LRP5 can cause high bone mass (HBM) by inhibiting sclerostin (SOST).
• Osteogenesis Imperfecta (OI) is a skeletal fragility disorder often caused by type I collagen mutations.

Purpose of the Study:

• To investigate if modulating the LRP5 pathway can improve bone properties in animal models of OI.
• To assess the therapeutic potential of LRP5 activation for OI.

Main Methods:

• Mated mice with an LRP5 HBM mutation (Lrp5(p.A214V)) to mice modeling type IV OI (Col1a2(+/p.G610C)).
• Treated OI model mice with a sclerostin-inhibiting monoclonal antibody (Scl-Ab).
• Assessed bone mass, strength, type I collagen mRNA expression, and collagen secretion.

Main Results:

• Offspring with both OI mutation and LRP5 HBM mutation showed significantly increased bone mass and strength.
• Scl-Ab treatment in OI model mice led to significant increases in bone mass and strength.
• Improved bone properties were independent of changes in type I collagen expression or secretion.

Conclusions:

• Activating the LRP5 pathway enhances bone mass and strength in OI models.
• Targeting bone formation pathways, like LRP5, offers a potential therapeutic strategy for OI.
• Therapeutic benefits can be achieved without altering collagen composition in OI models.